Tango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow TNGX
Tango Therapeutics, Inc. (TNGX) EV/Sales
As of 16 October 2026, Tango Therapeutics, Inc. (TNGX) trades at a EV/Sales of 36.7×. Over the past ten years it has ranged from −5.5× (September 2022) to 69.6× (June 2026); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 11.0× | 480.76% |
| FY2024 | 1.9× | (88.59%) |
| FY2023 | 16.6× | 49.85% |
| FY2022 | 11.1× | 111.81% |
| FY2021 | 5.2× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 11.0× | (6.16%) |
| Sep 2025 | 11.7× | (26.04%) |
| Jun 2025 | 15.8× | — |
| Mar 2025 | −1.6× | — |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 2.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.3× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| TNGX Tango Therapeutics, Inc. | 36.7× |
| ABCL AbCellera Biologics Inc. compare | 46.0× |
| RLAY Relay Therapeutics, Inc. compare | 217× |
| DNTH Dianthus Therapeutics, Inc. compare | 1,656× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)